Research and Markets: Top 50 Biotechnology Companies & Their Pipelines 2010

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/7467a0/top_50_biotechnolo) has announced the addition of the "Top 50 Biotechnology Companies & Their Pipelines 2010" report to their offering.

Despite economic turmoil, biotechnology companies in the U.S., Europe, Canada, and Australia had a combined net profit of $3.7 billion in 2009, a vast improvement from the $1.8 billion net loss in 2008. Biotech investment has improved as well with the Nasdaq Index currently exceeding its 2007 peak after bottoming out in 2008. New healthcare reform laws are expected to cost major biotech companies hundreds of millions of dollars in the short term, but will even out as marketers gain access to a wider patient pool. Overall, industry leaders are pleased with the reform's provisions for biosimilars, 12-year patent exclusivity, and tax credits for innovation.

The healthcare reform bill also includes the incentives necessary to attract the major investment required for the discovery and development of novel products. To offset the competition of biosimilars, biotechnology companies are expected to fill their pipelines with next-generation, break-through biologics as they look for ways to differentiate their portfolios. Major healthcare companies are making biologic and biosimilar development a priority. Merck & Co., which recently merged with Schering-Plough, has made biosimilars the focus of MerckBioVentures, a division created in December 2008. Following the company's recent portfolio prioritization, Merck has five novel biologics and two biosimilar candidates in clinical development. Moving forward, experts indicate that biotech firms will continue to face a challenging funding environment. Companies best poised for success are those that will increase financial and R&D efficiency and find creative models for funding and partnering.

Despite economic turmoil, biotechnology companies in the U.S., Europe, Canada, and Australia had a combined net profit of $3.7 billion in 2009, a vast improvement from the $1.8 billion net loss in 2008. Biotech investment has improved as well with the Nasdaq Index currently exceeding its 2007 peak after bottoming out in 2008.

The following information is included for the top 50 biotechnology companies (which were determined based on their healthcare revenue generated during 2009):

  • Each products chemical or substance composition, intended indication, clinical status, region of development, and developer/marketer
  • Pipeline status details preclinical development, Phase I, Phase II, Phase III, and awaiting approval
  • Region of development includes the U.S., Europe, and Japan
  • Select 2009 and 2008 financial data such as revenue, net income, earnings per share, and R&D expenditure An overview highlights the leading company pipelines and some of the most-promising drugs, including a Products to Watch section with sales and patent data.

Key Topics Covered:

  • Introduction with leading companies overview
  • 25 Special report methodology
  • 26 Healthcare revenue
  • 27 Healthcare R&D expenditure
  • 28 Net income and earnings per share
  • 29 Employees
  • 30 Location and year established
  • 30 Company financial notes
  • INDEX TO PIPELINES
  • Companies Mentioned

For more information visit http://www.researchandmarkets.com/research/7467a0/top_50_biotechnolo



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.